Postrelapse survival by level of urine-M protein or serum M-protein within 90 days of relapse. (A) In the absence of GEP-defined risk designation (TT1, TT2, and TT3 patients combined), postrelapse survival was significantly shorter when urinary M excretion exceeded 300 mg/day than in case of lower values. (B) In the absence of GEP-defined risk designation (TT1, TT2, and TT3 patients combined), postrelapse survival tended to be longer when serum-M levels exceeded 1.5 g/dL than in case of lower levels. (C) In the presence of GEP-defined risk designation, available in subsets of patients treated with TT2 and TT3, postrelapse survival was significantly shorter when urinary M excretion exceeded 300 mg/day than in case of lower values, regardless of GEP-defined risk (low risk, top panel; high risk, bottom panel). (D) In the presence of GEP-defined risk designation, available in subsets of patients treated with TT2 and TT3, postrelapse survival tended to be longer when serum-M levels exceeded 1.5 g/dL than in case of lower levels in the setting of low-risk myeloma (top panel) whereas, in the high-risk setting, postrelapse survival was significantly prolonged (bottom panel).